The Safety Profile of PRANDIN^®

Monitoring
No requirement for LFT monitoring*

Renal
May be used in patients with renal insufficiency**

Drug-drug
No drug interactions with digoxin, theophylline, warfarin, or cimetidine†

*Prandin^® should be used cautiously in patients with impaired liver function.

**No initial dose adjustment required for patients with mild to moderate renal dysfunction. Those with severe renal dysfunction should start with the 0.5-mg dose. Subsequent dosing increases should be made carefully.

†See full Prescribing Information for further drug interaction information.

In 1-year controlled trials comparing Prandin^® (n=1228) with sulfonylureas (n=498) for efficacy and safety, symptoms of mild to moderate hypoglycemia were reported in 16% of Prandin^®-treated patients; none developed coma or required hospitalization. Hypoglycemia was reported in 19 or 20% of patients treated with sulfonylureas (glyburide and glipizide, respectively). In placebo-controlled trials, 31% of patients treated with Prandin^® developed hypoglycemia.